Aridis Pharmaceuticals, Inc. (ARDS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
983 UNIVERSITY AVENUE, BLDG. B LOS GATOS, CA 95032 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 4,876 | 18,098 | 8,232 | 20,897 | 24,237 | |||
| Cash and cash equivalent | 4,876 | 18,098 | 8,232 | 20,897 | 24,237 | |||
| Restricted cash and investments | 183 | 1,388 | ||||||
| Receivables | 1,000 | 1,660 | ||||||
| Capitalized contract cost | 1,986 | 1,967 | 1,973 | 1,537 | ||||
| Other undisclosed current assets | 3,581 | 2,937 | 2,550 | 3,403 | 2,450 | |||
| Total current assets: | 11,626 | 24,390 | 12,755 | 25,837 | 28,347 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 1,417 | ✕ | ||||||
| Property, plant and equipment | 730 | 1,357 | 1,258 | 1,006 | 1,271 | |||
| Long-term investments and receivables | 9 | 960 | ||||||
| Long-term investments | 9 | 960 | ||||||
| Intangible assets, net (including goodwill) | 17 | 22 | 27 | 32 | 38 | |||
| Intangible assets, net (excluding goodwill) | 17 | 22 | 27 | 32 | 38 | |||
| Capitalized contract cost, net | 78 | 96 | 90 | 526 | ||||
| Restricted cash and investments | 500 | 500 | 500 | |||||
| Other noncurrent assets | 327 | 431 | 487 | 557 | 995 | |||
| Total noncurrent assets: | 3,069 | 2,406 | 2,362 | 2,130 | 3,264 | |||
| TOTAL ASSETS: | 14,695 | 26,796 | 15,117 | 27,967 | 31,611 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 11,872 | 11,704 | 3,216 | 4,729 | 5,275 | |||
| Accounts payable | 2,308 | 5,240 | 1,886 | 1,755 | 2,331 | |||
| Accrued liabilities | 9,564 | 6,464 | 1,330 | 2,974 | 2,944 | |||
| Deferred revenue | 20,173 | 20,838 | 18,748 | 14,602 | ✕ | |||
| Debt | 519 | 696 | 439 | |||||
| Other liabilities | 15 | 110 | 37 | |||||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | 22 | ||
| Other undisclosed current liabilities | 4,319 | |||||||
| Total current liabilities: | 36,898 | 33,348 | 22,440 | 19,331 | 5,297 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 5,282 | 276 | ||||||
| Long-term debt, excluding current maturities | 5,282 | 276 | ||||||
| Liabilities, other than long-term debt | 2,029 | 1,276 | 1,082 | 5,000 | ||||
| Deferred revenue | 737 | 913 | 854 | 5,000 | ✕ | |||
| Other liabilities | 363 | 228 | ||||||
| Operating lease, liability | 1,292 | ✕ | ||||||
| Total noncurrent liabilities: | 2,029 | 6,558 | 1,358 | 5,000 | ||||
| Total liabilities: | 38,927 | 39,906 | 23,798 | 24,331 | 5,297 | |||
| Equity | ||||||||
| Equity, attributable to parent | (24,232) | (13,110) | (8,681) | 3,636 | 26,314 | |||
| Common stock | 3 | 2 | 1 | 1 | 1 | |||
| Additional paid in capital | 166,380 | 152,183 | 114,420 | 104,404 | 97,401 | |||
| Accumulated other comprehensive income | 5,051 | |||||||
| Accumulated deficit | (195,666) | (165,295) | (123,102) | (100,769) | (71,088) | |||
| Total equity: | (24,232) | (13,110) | (8,681) | 3,636 | 26,314 | |||
| TOTAL LIABILITIES AND EQUITY: | 14,695 | 26,796 | 15,117 | 27,967 | 31,611 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 3,091 | 1,535 | 1,000 | 1,022 | 2,757 | ||
| Gross profit: | 3,091 | 1,535 | 1,000 | 1,022 | 2,757 | ||
| Operating expenses | (33,084) | (44,246) | (23,401) | (30,109) | (26,874) | ||
| Operating loss: | (29,993) | (42,711) | (22,401) | (29,087) | (24,117) | ||
| Interest and debt expense | 722 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (29,993) | (41,989) | (22,401) | (29,087) | (24,117) | ||
| Loss from equity method investments | (9) | (951) | (40) | ||||
| Loss from continuing operations: | (29,993) | (41,989) | (22,410) | (30,038) | (24,157) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (41,989) | (22,410) | (30,038) | (24,157) | |
| Other undisclosed net income (loss) | (204) | 77 | 357 | 2,052 | |||
| Net loss: | (29,993) | (42,193) | (22,333) | (29,681) | (22,105) | ||
| Other undisclosed net loss attributable to parent | (378) | ||||||
| Net loss attributable to parent: | (30,371) | (42,193) | (22,333) | (29,681) | (22,105) | ||
| Preferred stock dividends and other adjustments | (4,127) | (1,357) | |||||
| Net loss available to common stockholders, diluted: | (30,371) | (46,320) | (22,333) | (29,681) | (23,462) | ||
Comprehensive Income ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (29,993) | (42,193) | (22,333) | (29,681) | (22,105) | ||
| Other comprehensive income | 5,051 | ||||||
| Other undisclosed comprehensive income | |||||||
| Comprehensive income (loss): | (24,942) | (42,193) | (22,333) | (29,681) | (22,105) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (378) | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (25,320) | (42,193) | (22,333) | (29,681) | (22,105) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.